Search

1095 Result(s)
Sort by

Daniel Kiesenhofer

Daniel Kiesenhofer

Diverse, caring, collaborative - Daniel Kiesenhofer on Boehringer Ingelheim
Dirk Esser

Dirk Esser

Diverse, caring, collaborative - Dirk Esser on Boehringer Ingelheim
Ann-Kathrin Koller

Ann-Kathrin Koller

Diverse, caring, collaborative - Ann-Kathrin Koller on Boehringer Ingelheim
Diversity

Diversity

At Boeheringer Ingelheim, we believe in a diverse working culture. Find out what our people like most about working with us.
cystic fibrosis phase II trial

cystic fibrosis phase II trial

The first patient has been enrolled in a phase II trial to evaluate an innovative treatment for cystic fibrosis, inhaled via the Respimat® inhaler
Partnership canine oncology

Partnership canine oncology

The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.
FIBRONEER™ Phase III program initiated

FIBRONEER™ Phase III program initiated

FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor